ClassID:

20413

A61K31/499 - CPC Classification

Classification description:

Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring heteroatoms, e.g. piperazine Spiro-condensed pyrazines or piperazines

Recent Application in this class:
#1
20260137676
2026-05-21

PIPERAZINE SUBSTITUTED PHENOL DERIVATIVE AND USE THEREOF

#2
20260115182
2026-04-30

PAPD5 INHIBITORS AND METHODS OF USE THEREOF

#3
20260102396
2026-04-16

NEW THERAPEUTIC APPROACH TO LUNG DISEASE

#4
20260096985
2026-04-09

Injectable Composition For Drug Delivery

#5
20260092061
2026-04-02

COMPOUNDS FOR TARGETED PROTEIN DEGRADATION

#6
20260070904
2026-03-12

COMPOUNDS FOR TARGETED PROTEIN DEGRADATION

#7
20260055095
2026-02-26

NOVEL COMPOUNDS AND USES THEREOF

#8
20250376481
2025-12-11

POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION THEREOF

#9
20250360103
2025-11-27

METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2

#10
20250313574
2025-10-09

SIALIC ACID DERIVATIVES AND METHODS OF USING SAME

#11
20250304571
2025-10-02

BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF

#12
20250241926
2025-07-31

HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER

#13
20250230165
2025-07-17

HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER

#14
20250213558
2025-07-03

T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A PIPERAZINE OR 1,4-DIAZEPANE CORE AND METHODS OF USE THEREOF

#15
20250197374
2025-06-19

WEE1 DEGRADING COMPOUNDS AND USES THEREOF

#16
20250129021
2025-04-24

SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS

#17
20250091989
2025-03-20

SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS

#18
20250057829
2025-02-20

INHIBITORS OF TRPC6 FOR TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS

#19
20250034168
2025-01-30

NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE PARP INHIBITOR AND USE THEREOF

#20
20250019380
2025-01-16

PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF

#21
20250002471
2025-01-02

6-SUBSTITUTED INDOLE COMPOUNDS

#22
20240425523
2024-12-26

Compounds for the Degradation of EGFR Kinase

#23
20240425498
2024-12-26

PARG INHIBITORY COMPOUNDS

#24
20240374693
2024-11-14

TREATMENT AND DETECTION OF INHERITED NEUROPATHIES AND ASSOCIATED DISORDERS

#25
20240374587
2024-11-14

MEDICINE FOR PREVENTION AND TREATMENT OF DISEASES LINKED TO ANTI-OBESITY ACTIVITY

#26
20240342106
2024-10-17

NANOPARTICLES AND USES THEREOF FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS

#27
20240317721
2024-09-26

PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN

#28
20240239811
2024-07-18

5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T

#29
20240199614
2024-06-20

MACROCYCLIC EGFR INHIBITORS FOR THE TREATMENT OF CANCER

#30
20240197682
2024-06-20

METHOD FOR TREATING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS

#31
20240109906
2024-04-04

CDK INHIBITORS

#32
20240092880
2024-03-21

TREATMENT OF MIGRAINE

#33
20230293642
2023-09-21

TREATMENT AND DETECTION OF INHERITED NEUROPATHIES AND ASSOCIATED DISORDERS

#34
20230241059
2023-08-03

ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS

#35
20230219897
2023-07-13

Pyrazole MAGL inhibitors

#36
20230210851
2023-07-06

SPIRO-LACTAM COMPOUNDS AND METHODS OF TREATING VIRAL INFECTIONS USING THE SAME

#37
20230137816
2023-05-04

ADMINISTRATION OF CALCIUM CHANNEL TRPC6 INHIBITORS USING BALLOONS, STENTS OR OTHER MEDICAL DEVICES

#38
20230131402
2023-04-27

SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF

#39
20230049113
2023-02-16

METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2

#40
20230046776
2023-02-16

Compositions and methods for treating neurological disorders

#41
20220324835
2022-10-13

INHIBITORS OF CBL-B AND METHODS OF USE THEREOF

#42
20220249624
2022-08-11

Treatment and detection of inherited neuropathies and associated disorders

#43
20220249471
2022-08-11

NEW THERAPEUTIC APPROACH TO LUNG DISEASE

#44
20220193275
2022-06-23

INDUCING FAVORABLE EFFECTS ON TUMOR MICROENVIRONMENT VIA ADMINISTRATION OF NANOPARTICLE COMPOSITIONS

#45
20220152069
2022-05-19

Compounds and pharmaceutical uses thereof

#46
20220125890
2022-04-28

TREATMENT AND DETECTION OF INHERITED NEUROPATHIES AND ASSOCIATED DISORDERS

#47
20220088008
2022-03-24

Aromatic heterocyclic compound, and pharmaceutical composition and use thereof

#48
20210395259
2021-12-23

CDK INHIBITORS

#49
20210386702
2021-12-16

Method for inhibiting virus infection and replication

#50
20210379044
2021-12-09

NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES

#51
20210332046
2021-10-28

NICOTINIC ACETYLCHOLINE RECEPTOR SILENT AGONISTS

#52
20210330863
2021-10-28

5-HYDROXYTRYPTAMINE 1B RECEPTOR-STIMULATING AGENT FOR ENHANCING IN VIVO ENGRAFTMENT POTENTIAL

#53
20210322406
2021-10-21

Spiro-lactam NMDA receptor modulators and uses thereof

#54
20210283091
2021-09-16

DECREASING IMMUNE ACTIVITY THROUGH MODULATION OF POSTCELLULAR SIGNALING FACTORS

#55
20210251945
2021-08-19

Compounds and pharmaceutical uses thereof

#56
20210214448
2021-07-15

CCR5 BINDING AGENT FOR THE TREATMENT OF CCR5 POSITIVE METASTATIC CANCER

#57
20210177827
2021-06-17

PAPD5 inhibitors and methods of use thereof

#58
20210115065
2021-04-22

Compounds and compositions for the treatment of parasitic diseases

#59
20200338052
2020-10-29

Compositions and methods for treating neurological disorders

#60
20200281951
2020-09-10

Methods of treating anxiety by administering a substituted quinolone

#61
20200277300
2020-09-03

CDK inhibitors

#62
20200247804
2020-08-06

Nicotinic acetylcholine receptor silent agonists

#63
20200216406
2020-07-09

Benzothiophene estrogen receptor modulators

#64
20200172492
2020-06-04

Pharmaceutical compound

#65
20200163961
2020-05-28

Bicyclic compounds and methods for their use in treating autism

#66
20200022977
2020-01-23

Spirocycle compounds and methods of making and using same

#67
20190374526
2019-12-12

Substituted Heterocyclic Compounds as Inhibitors of PRDM9

#68
20190336489
2019-11-07

NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES

#69
20190175588
2019-06-13

Spiro-lactam NMDA receptor modulators and uses thereof

#70
20190151311
2019-05-23

Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors

#71
20190142852
2019-05-16

Method of treating disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine

#72
20190127375
2019-05-02

SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS

#73
20190127374
2019-05-02

SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS

#74
20190127373
2019-05-02

SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS

#75
20190119292
2019-04-25

CDK inhibitors

#76
20190119243
2019-04-25

Benzothiophene estrogen receptor modulators

#77
20190083490
2019-03-21

Composition comprising fine particle and process thereof

#78
20190071434
2019-03-07

Mutant IDH1 inhibitors useful for treating cancer

#79
20180362475
2018-12-20

Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death

#80
20180354908
2018-12-13

Pharmaceutical compound

#81
20180326121
2018-11-15

5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential

#82
20180298002
2018-10-18

Nicotinic acetylcholine receptor silent agonists

#83
20180230123
2018-08-16

Benzothiophene estrogen receptor modulators

#84
20180201619
2018-07-19

CDK inhibitors

#85
20180201618
2018-07-19

CDK inhibitors

#86
20180201617
2018-07-19

CDK inhibitors

#87
20180186791
2018-07-05

Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors

#88
20180186790
2018-07-05

Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors

#89
20180185360
2018-07-05

CGRP RECEPTOR ANTAGONIST COMPOUNDS FOR TOPICAL TREATMENT OF SKIN DISORDERS

#90
20180179203
2018-06-28

Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors

#91
20180140601
2018-05-24

Bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders

#92
20180065982
2018-03-08

Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death

#93
20170334924
2017-11-23

Spirocyclic heterocyclic compounds useful as HIV integrase inhibitors

#94
20170296536
2017-10-19

Ophthalmic suspension formulation

#95
20170283885
2017-10-05

ALGORITHMS FOR GENE SIGNATURE-BASED PREDICTOR OF SENSITIVITY TO MDM2 INHIBITORS

#96
20170275283
2017-09-28

Inhibitors of the renal outer medullary potassium channel

#97
20170253615
2017-09-07

Spirocyclic derivatives

#98
20170182043
2017-06-29

Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat RB-positive tumors

#99
20170145011
2017-05-25

Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels

#100
20170107222
2017-04-20

Pyridyl piperidines

#101
20170096425
2017-04-06

Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors

#102
20170057971
2017-03-02

CDK inhibitors

#103
20170044156
2017-02-16

Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as HIV integrase inhibitor

#104
20170044132
2017-02-16

Heterocyclic compound

#105
20170020869
2017-01-26

Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders

#106
20160317543
2016-11-03

Spirocyclic hetercycle compounds useful as HIV integrase inhibitors

#107
20160222025
2016-08-04

Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death

#108
20160115132
2016-04-28

Phenol derivatives and pharmaceutical or cosmetic use thereof

#109
20160058757
2016-03-03

HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE

#110
20160046641
2016-02-18

SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR

#111
20150353548
2015-12-10

2-aminopyridine compounds

#112
20150322045
2015-11-12

Substituted cyanoguanidines as oral anti-virals

#113
20150246926
2015-09-03

CDK inhibitors

#114
20150246925
2015-09-03

CDK inhibitors

#115
20150174127
2015-06-25

Substituted spiro[piperidine-4,1'-pyrrolo[1,2-a]pyrazine]s as modulators of ion channels

#116
20140302009
2014-10-09

Medicinal Agent for Prevention or Treatment of Diseases Associated with Intraocular Neovascularization and/or Intraocular Vascular Hyperpermeability

#117
20140275536
2014-09-18

Phenol derivatives and pharmaceutical or cosmetic use thereof

#118
20140221380
2014-08-07

SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR

#119
20140179634
2014-06-26

Substituted indole derivatives

#120
20140147448
2014-05-29

Compositions and methods of preventing or ameliorating abnormal thrombus formation and cardiovascular disease

#121
20140093518
2014-04-03

Chemically Programmed Vaccination

#122
20140066369
2014-03-06

Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto

#123
20130237535
2013-09-12

FATTY ACID SYNTHASE INHIBITORS

#124
20130172362
2013-07-04

Imidazothiazole Derivatives Having Proline Ring Structure

#125
20130157980
2013-06-20

Substituted indole derivatives

#126
20130096111
2013-04-18

Methods involving aldose reductase inhibitors

#127
20130023529
2013-01-24

Methods involving aldose reductase inhibitors

#128
20130023496
2013-01-24

Combination Therapy Comprising A CCR5 Antagonist, A HIV-1 Protease Inhibtior and a Pharmacokinetic Enhancer

#129
20120196869
2012-08-02

Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels

#130
20110311516
2011-12-22

Chemically programmed vaccination

#131
20110301176
2011-12-08

Imidazothiazole derivatives having proline ring structure

#132
20110245256
2011-10-06

Use of a PKC inhibitor

#133
20110052612
2011-03-03

SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF

#134
20110052531
2011-03-03

Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy

#135
20100222354
2010-09-02

AMPA Receptor Antagonists and Aldose Reductase Inhibitors for Neuropathic Pain

#136
20100179175
2010-07-15

USE OF PKC INHIBITORS IN OCULAR DISEASES

#137
20100144748
2010-06-10

Methods involving aldose reductase inhibitors

#138
20070270429
2007-11-22

Function Inhibitor of Effector Cell

#139
20070244188
2007-10-18

Anti-first-pass effect compounds

#140
20070155713
2007-07-05

Nitrogen-containing heterocyclic compounds and use thereof

#141
20060269599
2006-11-30

Fast-dissolving pharmaceutical composition

#142
20060189591
2006-08-24

Five-membered heterocyclic derivative

#143
20060160859
2006-07-20

Method for treating HIV infection through co-administration of tipranavir and GW873140

#144
20060058310
2006-03-16

Remedies for vertebral canal stenosis

#145
20050214366
2005-09-29

Anti-first-pass effect compounds

#146
16986188
2023-08-15

Compositions and methods for modulating the endothelial barrier